再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09688 再鼎医药

收市竞价 05-08 16:02:46

22.300

-0.350

-1.55%

最高22.800	最低22.000	成交量829.24万
今开22.650	昨收22.650	日振幅3.53%
总市值245.97亿	流通市值245.97亿	总股本11.03亿
成交额1.85亿	换手率0.75%	流通股本11.03亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"再鼎医药","latestPrice":22.3,"timestamp":1746691360029,"preClose":22.65,"halted":0,"volume":8292400,"delay":0,"floatShares":1103000000,"shares":1103000000,"eps":-2.019312070627001,"marketStatus":"收市竞价","change":-0.35,"latestTime":"05-08 16:02:46","open":22.65,"high":22.8,"low":22,"amount":184769090,"amplitude":0.03532,"askPrice":22.3,"askSize":177800,"bidPrice":22.3,"bidSize":188200,"shortable":3,"etf":0,"ttmEps":-2.019312070627001,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1746691800000},"marketStatusCode":4,"adr":0,"listingDate":1601222400000,"exchange":"SEHK","adjPreClose":22.65,"openAndCloseTimeList":[[1746667800000,1746676800000],[1746680400000,1746691200000]],"volumeRatio":0.875777,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09688/wiki","defaultTab":"wiki","newsList":[{"id":"2532897643","title":"每日卖空追踪 | 再鼎医药 05月02日卖空量成交34.87万股，卖空比例为11.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532897643","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532897643?lang=zh_cn&edition=full","pubTime":"2025-05-02 16:30","pubTimestamp":1746174640,"startTime":"0","endTime":"0","summary":"再鼎医药北京时间05月02日，涨2.86%，卖空量成交34.87万股，较上一交易日减少52.28%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502163909a6d0e672&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502163909a6d0e672&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","BK1574","BK1161","LU2488822045.USD","BK1588"],"gpt_icon":0},{"id":"2532976894","title":"再鼎医药05月02日获主力加仓495.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532976894","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532976894?lang=zh_cn&edition=full","pubTime":"2025-05-02 16:15","pubTimestamp":1746173741,"startTime":"0","endTime":"0","summary":"05月02日, 再鼎医药股价涨2.86%，报收25.20元，成交金额7223.2万元，换手率0.27%，振幅5.71%，量比0.32。再鼎医药今日主力资金净流入495.8万元，上一交易日主力净流入2525.0万元。该股近5个交易日下跌2.50%，主力资金累计净流入5787.1万元；近20日主力资金累计净流入3.4亿元，其中净流入天数为16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502162418a46fc801&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502162418a46fc801&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","BK1574","BK1161","LU2488822045.USD","BK1588"],"gpt_icon":0},{"id":"2530528494","title":"港股生物技术股多数走低，康方生物跌超12%，云康集团跌超6%，思路迪医药股份、再鼎医药跌超4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530528494","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530528494?lang=zh_cn&edition=full","pubTime":"2025-04-28 10:14","pubTimestamp":1745806482,"startTime":"0","endTime":"0","summary":"港股生物技术股多数走低，康方生物跌超12%，云康集团跌超6%，思路迪医药股份、再鼎医药跌超4%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/28101449938498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK4526","LU0417516571.SGD","BK4139","02325","LU0348784397.USD","BK4548","BK4588","ZLAB","LU1720050803.USD","BK4614","BK1161","09926","IE00B5MMRT66.SGD","IE00B543WZ88.USD","BK4585","01244","LU0348783233.USD","IE00BPRC5H50.USD","HSCEI","BK1588","BK1219","BK4531","HSTECH","LU1794554557.SGD","YANG","LU2488822045.USD","09688"],"gpt_icon":0},{"id":"2530499592","title":"【港股医药股走低 康方生物跌超15%】截至发稿，康方生物(09926.HK)跌15.07%、宜明昂科-B(01541.HK)跌9.75%、再鼎医药(09688.HK)跌6.43%、加科思-B(01167.HK)跌5.37%、腾盛博药-B(02137.HK)跌5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530499592","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530499592?lang=zh_cn&edition=full","pubTime":"2025-04-28 09:40","pubTimestamp":1745804429,"startTime":"0","endTime":"0","summary":"截至发稿，康方生物(09926.HK)跌15.07%、宜明昂科-B(01541.HK)跌9.75%、再鼎医药(09688.HK)跌6.43%、加科思-B(01167.HK)跌5.37%、腾盛博药-B(02137.HK)跌5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/28094049937146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4531","LU0348783233.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","02137","09688","BK4139","IE00BPRC5H50.USD","BK1161","BK4585","LU0417516571.SGD","IE00B543WZ88.USD","LU0348784397.USD","LU2488822045.USD","09926","01541","BK1588","BK4526","159718","LU1720050803.USD","ZLAB","BK4548","BK1587","BK4588","01167","BK1574"],"gpt_icon":0},{"id":"2530467499","title":"再鼎医药盘中异动 早盘股价大跌5.65%报24.200港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530467499","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530467499?lang=zh_cn&edition=full","pubTime":"2025-04-28 09:30","pubTimestamp":1745803809,"startTime":"0","endTime":"0","summary":"2025年04月28日早盘09时30分，再鼎医药股票出现异动，股价快速跳水5.65%。截至发稿，该股报24.200港元/股，成交量8.77万股，换手率0.01%，振幅3.31%。资金方面，该股资金流入90.6015万港元，流出60.7805万港元。再鼎医药股票所在的生物技术行业中，整体跌幅为2.03%。其相关个股中，来凯医药-B、锦欣生殖、维亚生物涨幅较大，振幅较大的相关个股有康方生物、再鼎医药、复宏汉霖，振幅分别为3.74%、3.31%、2.91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428093009aa2c7c35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428093009aa2c7c35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1161","LU2488822045.USD","BK1574","09688"],"gpt_icon":0},{"id":"2529953808","title":"再鼎医药拟5月8日举行董事会会议批准一季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2529953808","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529953808?lang=zh_cn&edition=full","pubTime":"2025-04-24 22:27","pubTimestamp":1745504830,"startTime":"0","endTime":"0","summary":"格隆汇4月24日丨再鼎医药(09688.HK)公告，董事会审核委员会将于2025年5月8日(星期四)审议及批准(其中包括)根据美国公认会计准则及美国证券交易委员会的适用规则编制的公司及其附属公司截至2025年3月31日止3个月的未经审核季度业绩(\"第一季度业绩\")及其发布。【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504242233599743bb12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504242233599743bb12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","09688","BK1161","BK1588","BK1574"],"gpt_icon":0},{"id":"2529795446","title":"再鼎医药04月24日主力净流出321万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2529795446","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529795446?lang=zh_cn&edition=full","pubTime":"2025-04-24 16:15","pubTimestamp":1745482538,"startTime":"0","endTime":"0","summary":"04月24日, 再鼎医药股价跌0.19%，报收25.95元，成交金额2.73亿元，换手率0.95%，振幅5.77%，量比0.88。再鼎医药今日主力资金净流出321万元，上一交易日主力净流入710万元。该股近5个交易日上涨6.20%，主力资金累计净流入667万元；近20日主力资金累计净流入3.26亿元，其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424165804a6c654f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424165804a6c654f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","BK1574","BK1161","BK1588","LU2488822045.USD"],"gpt_icon":0},{"id":"2529613094","title":"不限癌种！再鼎医药突破性口服新药新适应症申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2529613094","media":"药渡","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529613094?lang=zh_cn&edition=full","pubTime":"2025-04-24 07:30","pubTimestamp":1745451046,"startTime":"0","endTime":"0","summary":"4月21日，中国国家药监局药品审评中心官网最新公示，由百时美施贵宝公司申报的瑞普替尼胶囊新适应症上市申请已获得受理。针对该项适应症，瑞普替尼此前已经被CDE正式纳入优先审评。再鼎医药新闻稿表示，瑞普替尼有望成为新一代TKI药物，可广泛用于治疗不同瘤种的NTRK融合阳性实体瘤患者，包括TKI初治和TKI经治患者。本次瑞普替尼针对NTRK融合阳性实体瘤适应症正式在中国申报上市，意味着其有望在不久的将来惠及更多患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424094457a464a25f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424094457a464a25f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","09688","BK1161","BK1574","BK1588"],"gpt_icon":0},{"id":"1173712019","title":"异动解读 | 再鼎医药股价盘中大涨5.53%，或与200万股新股发行有关","url":"https://stock-news.laohu8.com/highlight/detail?id=1173712019","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173712019?lang=zh_cn&edition=full","pubTime":"2025-04-23 09:32","pubTimestamp":1745371965,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中大涨5.53%，引起市场广泛关注。这一涨幅可能与公司最新公告的股票发行有关。根据再鼎医药发布的公告，公司于2025年4月22日发行了200万股新股。通常情况下，新股发行可能会导致股价下跌，因为会稀释现有股东的权益。然而，再鼎医药股价不降反升，这可能反映了市场对公司股权激励计划的积极看法。此外，市场可能将此解读为公司管理层对未来发展前景充满信心的信号，进而推动了股价上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09688"],"gpt_icon":0},{"id":"1155113454","title":"异动解读 | 再鼎医药因发行新股盘中大涨5.53%，股权激励计划引发市场积极反应","url":"https://stock-news.laohu8.com/highlight/detail?id=1155113454","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155113454?lang=zh_cn&edition=full","pubTime":"2025-04-23 09:32","pubTimestamp":1745371955,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中大涨5.53%，引发市场关注。这一显著涨幅可能与公司最新公告的股份发行有关。根据再鼎医药发布的公告，公司于2025年4月22日发行了200万股新股。市场对这一消息反应积极，可能是因为投资者认为这表明公司正在积极实施其长期激励计划，有助于吸引和留住人才，从而推动公司的长期发展。股权激励计划通常被视为公司对未来发展前景持乐观态度的信号，这可能是推动股价上涨的主要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 再鼎医药因发行新股盘中大涨5.53%，股权激励计划引发市场积极反应","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09688"],"gpt_icon":0},{"id":"2529593121","title":"再鼎医药4月22日发行新股200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2529593121","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529593121?lang=zh_cn&edition=full","pubTime":"2025-04-23 08:22","pubTimestamp":1745367720,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　再鼎医药（09688）发布公告，于2025年4月22日因兑现按先前披露的条款（1）归属根据 2017，2022及2024年股权激励计划所授出的非期权奖励，及（2）如适用，行使根据2015，2017，2022及2024年股权激励计划所授出的购股权发行新股200万股。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-23/doc-ineuccea3438380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","ZLAB","LU2488822045.USD","BK4139","BK1161","BK4548","BK1574","BK4531","BK1588","09688","BK4526","BK4588"],"gpt_icon":0},{"id":"2529630675","title":"再鼎医药(09688)4月22日发行新股200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2529630675","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529630675?lang=zh_cn&edition=full","pubTime":"2025-04-22 20:21","pubTimestamp":1745324463,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，于2025年4月22日因兑现按先前披露的条款(1)归属根据 2017，2022及2024年股权激励计划所授出的非期权奖励，及(2)如适用，行使根据2015，2017，2022及2024年股权激励计划所授出的购股权发行新股200万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","ZLAB","BK4548","BK1574","BK4588","BK4526","BK4531","BK1588","BK4139","09688","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2529943371","title":"再鼎医药(ZLAB)盘前涨超7% 瑞普替尼新适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2529943371","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529943371?lang=zh_cn&edition=full","pubTime":"2025-04-22 18:52","pubTimestamp":1745319158,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药(ZLAB)盘前涨超7%，截至发稿，报31.87美元。消息面上，4月21日，再鼎医药宣布，国家药品监督管理局（NMPA）已受理瑞普替尼（repotrectinib）的补充新药上市申请（sNDA），用于治疗携带神经营养酪氨酸受体激酶（NTRK）基因融合的实体瘤成人患者，该类患者为局部晚期、转移性，或手术切除可能导致严重并发症的患者，且这些患者在接受既往治疗后出现疾病进展，或缺乏有效的治疗方案选择。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/OWU4OGExOTI2NzgyMTc2NjE0.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/OWU4OGExOTI2NzgyMTc2NjE0.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"287723","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4531","BK4585","BK1588","09688","BK1161","BK4526","BK1574","BK4548","BK4139","LU2488822045.USD","ZLAB","BK4588"],"gpt_icon":0},{"id":"2529321023","title":"再鼎医药04月22日主力净流入1772万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529321023","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529321023?lang=zh_cn&edition=full","pubTime":"2025-04-22 16:16","pubTimestamp":1745309799,"startTime":"0","endTime":"0","summary":"04月22日, 再鼎医药股价涨7.02%，报收24.40元，成交金额3.16亿元，换手率1.18%，振幅7.24%，量比0.93。再鼎医药今日主力资金净流入1772万元，上一交易日主力净流出205万元。该股近5个交易日上涨8.78%，主力资金累计净流入3686万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入3.03亿元，其中净流入天数为15日。该股主力净额占比0.07%，港股市场排名108/2647。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422171344a4623b90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422171344a4623b90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1161","BK1588","09688","BK1574"],"gpt_icon":0},{"id":"2529345581","title":"港股异动 | 再鼎医药(09688)涨超7% 瑞普替尼新适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2529345581","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529345581?lang=zh_cn&edition=full","pubTime":"2025-04-22 15:34","pubTimestamp":1745307273,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药涨超7%，截至发稿，涨7.02%，报24.4港元，成交额2.79亿港元。另外，公司合作伙伴argenx近日宣布，艾加莫德预充针皮下注射剂型获美国FDA批准上市。据悉，目前在国内，艾加莫德已有静脉输注和皮下注射2种给药方式。再鼎医药将于2025年在国内递交艾加莫德预充式皮下注射剂型的上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ZLAB","BK4585","BK1161","LU2488822045.USD","BK4531","BK1588","BK4548","BK1574","BK4526","09688","BK4588","BK4139"],"gpt_icon":0},{"id":"2529391901","title":"港股医药逆势走强 港股医药ETF涨超3% 冲击四连涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2529391901","media":"东方财富证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529391901?lang=zh_cn&edition=full","pubTime":"2025-04-22 11:10","pubTimestamp":1745291400,"startTime":"0","endTime":"0","summary":"4月22日，港股市场集体震荡环境下，港股医药带头领涨，港股医药ETF上涨3.10%，冲击4连涨。成分股石药集团、百济神州、信达生物、再鼎医药、康方生物上涨超 5%。港股医药ETF紧密跟踪中证港股通医药卫生综合指数，中证港股通医药卫生综合指数从港股通范围内选取50只流动性较好、市值较大的医疗卫生行业上市公司证券作为指数样本，以反映港股通范围内医药卫生上市公司证券的整体表现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422111145a6c32f7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422111145a6c32f7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","BK1191","LU0326950275.SGD","BK1515","01801","01093","LU1807302812.USD","IE00BZ08YR35.GBP","LU0067412154.USD","LU1226288253.USD","LU0880133367.SGD","LU1008478684.HKD","IE0008368742.USD","LU1951186391.HKD","06160","SG9999004220.SGD","IE00B543WZ88.USD","09688","LU1226287529.USD","IE00BZ08YT58.USD","LU1960683339.HKD","LU1993786604.SGD","LU0072913022.USD","LU1226287875.USD","IE00B5MMRT66.SGD","IE00B031HY20.USD","LU0501845795.SGD","LU1226287792.SGD","BK1521","LU1152091754.HKD","LU1226288170.HKD","LU0140636845.USD","IE0008369823.USD","09926","LU1152091168.USD","IE00BZ08YS42.EUR"],"gpt_icon":1},{"id":"1167239425","title":"异动解读 | 再鼎医药盘中大涨7.46%，南向资金持续加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=1167239425","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167239425?lang=zh_cn&edition=full","pubTime":"2025-04-22 10:12","pubTimestamp":1745287947,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中大涨7.46%，引发市场关注。分析人士认为，这一涨幅可能与南向资金持续加仓有关。截至当日收盘，港股通共持有再鼎医药1.99亿股，占流通股18.10%。值得注意的是，再鼎医药近5个交易日上涨4.59%，期间港股通累计增持2105.94万股；虽然近20个交易日下跌23.62%，但港股通仍累计增持4455.90万股，显示出南向资金对该股的持续看好。然而，投资者仍需警惕市场风险，密切关注公司基本面变化和行业动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 再鼎医药盘中大涨7.46%，南向资金持续加仓","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09688"],"gpt_icon":0},{"id":"2528892760","title":"再鼎医药04月17日遭主力抛售205万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528892760","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528892760?lang=zh_cn&edition=full","pubTime":"2025-04-17 16:15","pubTimestamp":1744877758,"startTime":"0","endTime":"0","summary":"04月17日, 再鼎医药股价跌1.30%，报收22.80元，成交金额2.34亿元，换手率0.93%，振幅5.19%，量比0.66。再鼎医药今日主力资金净流出205万元，上一交易日主力净流出1291万元。该股近5个交易日上涨5.73%，主力资金累计净流入1.48亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2.87亿元，其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417170254a45c4321&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417170254a45c4321&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1588","LU2488822045.USD","09688","BK1161"],"gpt_icon":0},{"id":"2528781917","title":"中金：维持再鼎医药(09688)跑赢行业评级 目标价34.41港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528781917","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528781917?lang=zh_cn&edition=full","pubTime":"2025-04-17 09:15","pubTimestamp":1744852527,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持再鼎医药2025年和2026年盈利预测不变。该行维持跑赢行业评级，基于DCF模型，该行维持H/US股目标价34.41港元/44.24美元不变。4月11日，公司合作伙伴argenx宣布艾加莫德预充针皮下注射剂型获美国FDA批准上市。目前在国内，艾加莫德已有静脉输注和皮下注射2种给药方式，公司将于2025年在国内递交艾加莫德预充式皮下注射剂型的上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1279879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ZLAB","09688"],"gpt_icon":1},{"id":"2527970172","title":"高盛研报：重症肌无力市场格局重塑？强烈看好再鼎医药艾加莫德绝对竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2527970172","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527970172?lang=zh_cn&edition=full","pubTime":"2025-04-16 18:53","pubTimestamp":1744800794,"startTime":"0","endTime":"0","summary":"艾加莫德的快速起效特性，使其在急性和难治性患者中尤为受欢迎。这可能成为未来竞争格局中推动艾加莫德市场份额扩大的重要因素。这表明艾加莫德可以作为一种可靠的维持治疗方案。“研究外”要素不容忽视高盛的报告指出，随着重症肌无力药物选择的愈加丰富，除了临床数据外，还有诸多“临床研究外”因素可能影响竞争格局。高盛认为，这一时间差为艾加莫德提供了至少两年的市场先发优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504161857109739d59c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504161857109739d59c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","BK1574","LU2488822045.USD","BK1161","BK1588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.0755},{"period":"1month","weight":0.0486},{"period":"3month","weight":0.039},{"period":"6month","weight":-0.0774},{"period":"1year","weight":0.745},{"period":"ytd","weight":0.0837}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":0.1444},{"period":"3month","weight":0.0862},{"period":"6month","weight":0.0947},{"period":"1year","weight":0.228},{"period":"ytd","weight":0.1312}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"再鼎医药有限公司是一家主要从事生物制药的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、自身免疫疾病、感染性疾病和中枢神经系统疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.013207},{"month":2,"riseRate":0.6,"avgChangeRate":0.053227},{"month":3,"riseRate":0.2,"avgChangeRate":-0.100669},{"month":4,"riseRate":0.6,"avgChangeRate":0.032813},{"month":5,"riseRate":0.4,"avgChangeRate":-0.035562},{"month":6,"riseRate":0.25,"avgChangeRate":-0.052584},{"month":7,"riseRate":0.75,"avgChangeRate":0.064885},{"month":8,"riseRate":0.75,"avgChangeRate":0.004625},{"month":9,"riseRate":0.25,"avgChangeRate":-0.078066},{"month":10,"riseRate":0.6,"avgChangeRate":-0.01228},{"month":11,"riseRate":0.6,"avgChangeRate":0.099288},{"month":12,"riseRate":0.4,"avgChangeRate":-0.001944}],"exchange":"SEHK","name":"再鼎医药","nameEN":"ZAI LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,09688,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}